SHOC2 and NRAS

Number of citations of the paper that reports this interaction (PubMedID 9674433)
58

Data Source:
HPRD (in vitro, two hybrid, in vivo)

		SHOC2	NRAS
Description		SHOC2 leucine rich repeat scaffold protein	NRAS proto-oncogene, GTPase
Image		No pdb structure
GO Annotations	Cellular Component	Protein Phosphatase Type 1 Complex Nucleus Nucleoplasm Cytoplasm Cytosol	Golgi Membrane Golgi Apparatus Plasma Membrane Membrane Extracellular Exosome Tertiary Granule Membrane
	Molecular Function	Protein Binding Protein Phosphatase 1 Binding Protein Phosphatase Regulator Activity Protein Phosphatase Binding	GTPase Activity Protein Binding GTP Binding GDP Binding Protein-containing Complex Binding
	Biological Process	Ras Protein Signal Transduction Fibroblast Growth Factor Receptor Signaling Pathway Regulation Of Phosphoprotein Phosphatase Activity Positive Regulation Of Ras Protein Signal Transduction	MAPK Cascade Positive Regulation Of Endothelial Cell Proliferation Stimulatory C-type Lectin Receptor Signaling Pathway Ras Protein Signal Transduction Neutrophil Degranulation
Pathways			SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants
Drugs
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Multiple myeloma Adrenal carcinoma Thyroid cancer Hepatocellular carcinoma Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS Malignant melanoma
GWAS			Autism ( 24189344)
Interacting Genes		8 interacting genes: APP ERBIN HRAS KRAS NRAS PSMC5 RAF1 UBE2D3	25 interacting genes: ACVR1 ARHGAP4 BCL2 DNAJB1 EEF1A1 HRAS LZTR1 MAPKAP1 MTOR PIK3CA PIK3CG PLCE1 RACGAP1 RAF1 RAP1GDS1 RASGRP2 RASSF5 RGL2 RPS20 SHOC2 SMAD4 SMURF2 SRI UBE2L3 WDR76
Entrez ID		8036	4893
HPRD ID		04144	01273
Ensembl ID		ENSG00000108061	ENSG00000213281
Uniprot IDs		Q9UQ13	P01111 Q5U091
PDB IDs			2N9C 3CON 5UHV 6E6H
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?